Novelty:
This technology identifies a novel myonectin protein, which links skeletal muscle to metabolic regulation. Myonectin was found to lower circulating free fatty acid levels by promoting lipid uptake.
Value Proposition:
Type-2 diabetes, obesity, and metabolic syndrome are diseases that dramatically reduce patient quality of life and lead to other ailments. This discovery helps shed light on responses to energy states and mediation of metabolism that can be applied to understand and treat metabolic diseases. The specific novel myonectic-mediated metabolic circuit could expose potential for improving physiological states or functions. Other advantages include:
• Development of therapeutic methods to treat or prevent diabetes or obesity.
• Possible regulation of abnormal metabolic function and better control of metabolic syndromes.
• Revealing further ways to mediate metabolic circuits.
Technical Details:
Johns Hopkins researchers have shown that circulation of a myonectin protein, synthesized and secreted by skeletal muscle, functions to link skeletal muscle to lipid metabolism in liver and adipose tissue. The link has been shown to possess the potential to lower fatty acid levels by increasing uptake of circulating lipids. The plasma levels of myonectin are lower in obese patients. This newly discovered myonectin-mediated metabolic circuit presents the potential for protein therapy of metabolic conditions.
Looking for Partners:
To develop and commercialize this platform as a protein therapeutic to lower blood free fatty acid levels in patients suffering from type-2 diabetes, obesity and metabolic syndrome.
Stage of Development:
Discovery
Data Availability:
Under CDA/NDA
Publications/Associated Cases:
Not available at this time.
